...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis
【24h】

Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis

机译：口腔福辛霉素免受鼠肾盂肾炎抗性大肠杆菌抗性菌株的意外活动

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Fosfomycin tromethamine activity is well established for oral treatment of uncomplicated lower urinary tract infections, but little is known about its potential efficacy in pyelonephritis. Ascending pyelonephritis was induced in mice infected with 6 strains of Escherichia coli (fosfomycin MICs, 1 mu g/ml to 256 mu g/ml). The urine pH was 4.5 before infection and 5.5 to 6.0 during infection. Animals were treated for 24 h with fosfomycin (100 mg/kg of body weight subcutaneously every 4 h), and the CFU were enumerated in kidneys 24 h after the last fosfomycin injection. Peak (20.5 mu g/ml at 1 h) and trough (3.5 mu g/ml at 4 h) levels in plasma were comparable to those obtained in humans after an oral dose of 3 g. Fosfomycin treatment significantly reduced the bacterial loads in kidneys (3.65 log(10) CFU/g [range, 1.83 to 7.03 log(10) CFU/g] and 1.88 log(10) CFU/g [range, 1.78 to 5.74 log(10) CFU/g] in start-of-treatment control mice and treated mice, respectively; P < 10(-6)). However, this effect was not found to differ across the 6 study strains (P = 0.71) or between the 3 susceptible and the 3 resistant strains (P = 0.09). Three phenomena may contribute to explain this unexpected in vivo activity: (i) in mice, the fosfomycin kidney/plasma concentration ratio increased from 1 to 7.8 (95% confidence interval, 5.2, 10.4) within 24 h in vitro when the pH decreased to 5, (ii) the fosfomycin MICs for the 3 resistant strains (64 to 256 mu g/ml) decreased into the susceptible range (16 to 32 mu g/ml), and (iii) maximal growth rates significantly decreased for all strains and were the lowest in urine. These results suggest that local fosfomycin concentrations and physiological conditions may favor fosfomycin activity in pyelonephritis, even against resistant strains.
机译：Fosfomycin Tromethamine活性对于口服治疗不复杂的低尿路感染是很好的，但对其肾盂肾炎的潜在疗效知之甚少。在感染6株大肠杆菌（FOSFOMYCIN MICS，1μg/ mL至256μg/ ml）的小鼠中诱导升肾盂肾炎。感染前的尿pH为4.5，感染期间5.5至6.0。将动物用FOSFOMYCIN（每4小时皮下皮下皮下皮下注射100mg / kg体重），并在最后的FOSFOMYCIN注射后24小时列举CFU。峰值（20.5μmg/ ml在1小时，4小时4小时，3.5μg/ ml）血浆水平与在3g中的口服剂量后的人类中获得的那些相当。 Fosfomycin治疗显着降低了肾脏的细菌载荷（3.65 log（10）Cfu / g [范围，1.83至7.03 log（10）Cfu / g]和1.88 log（10）Cfu / g [范围，1.78至5.74 log（10 ）CFU / g]分别在治疗开始和处理的小鼠中; P <10（6））。然而，没有发现这种效果在6个研究菌株（P = 0.71）或3易感和3个抗性菌株之间不同（P = 0.09）。三种现象可能有助于解释该意外的体内活动：（i）在小鼠中，当pH值下降时，FOSFOMCIN肾/等离子体浓度比在24小时内从24小时内增加1至7.8（95％置信区间，5.2,10.4）如图5所示，（ii）3抗抗菌菌株（64至256μg/ ml）的FOSFOMYCIN MIC降至易感范围（16至32μg/ ml）中，并且（III）所有菌株和最大生长率明显降低尿液中最低。这些结果表明，局部杂霉素浓度和生理条件可能有利于肾盂肾炎中的福斯霉素活性，即使是抗抗性菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号